"We are encouraged by the continued positive data from our Phase 2 trial of NP=G2-044, which highlight the therapeutic opportunity of our first-in-class fascin inhibitor for patients with advanced and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback